|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Improving recognition of hepatic perivascular epithelioid cell tumor:Case report and literature review显示文摘A 58-year-old man presented with the chief complaint of abdominal bloating and was incidentally found to have a liver tumor.As diagnostic imaging studies could not rule out malignancy,the patient underwent partial resection of segment 3 of the liver.The lesion pathologically showed eosinophilic proliferation,in addition to immunohistochemical positivity for human melanoma black 45 and Melan-A,thereby leading to the diagnosis of a hepatic perivascular epithelioid cell tumor(PEComa).A PEComa arising from the liver is relatively rare.Moreover,the name ‘PEComa' has not yet been widely recognized,and the same disease entity has been called epithelioid angiomyolipoma(EAML),further diminishing the recognition of PEComa.In addition,PEComa imaging findings mimic those of malignant liver tumors,and clinically,this tumor tends to enlarge.Therefore,a PEComa is difficult to diagnose.We conducted a systematic review of PEComa and EAML cases and discuss the results,including findings useful for differentiating perivascular epithelioid cell tumors from malignant liver tumors. | Toshiya Maebayashi Katsumi Abe Takuya Aizawa Masakuni Sakaguchi Naoya Ishibashi Osamu Abe Tadatoshi Takayama Hisashi Nakayama Shunichi Matsuoka Kazushige Nirei Hitomi Nakamura Masahiro Ogawa Masahiko Sugitani | 2015 | World Journal of Gastroenterology2015，21，17： | 20 |
| 2 | Surgical treatment of hepatocellular carcinoma: Evidence-based outcomes显示文摘Surgeons may be severely criticized from the perspective of evidence-based medicine because the majority of surgical publications appear not to be convincing. In the top nine surgical journals in 1996, half of the 175 publications refer to pilot studies lacking a control group, 18% to animal experiments, and only 5% to randomized controlled trials (RCT). There are five levels of clinical evidence:level 1 (randomized controlled trial), level 2 (prospective concurrent cohort study), level 3 (retrospective historical cohort study), level 4 (pre-post study), and level 5 (case report). Recently, a Japanese evidence-based guideline for the surgical treatment of hepatocellular carcinoma (HCC) was made by a committee (Chairman, Professor Makuuchi and five members). We searched the literature using the Medline Dialog System with four Keywords:HCC, surgery, English papers, in the last 20 years. A total of 915 publications were identified systematically reviewed. At the first selection (in which surgery-dominant papers were selected), 478 papers survived. In the second selection (clearly concluded papers), 181 papers survived. In the final selection (clinically significant papers), 100 papers survived. The evidence level of the 100 surviving papers is shown here:level-1 papers (13%), level-2 papers (11%), level-3 papers (52%), and level-4 papers (24%);therefore, there were 24% prospective papers and 76% retrospective papers. Here, we present a part of the guideline on the five main surgical issues:indication to operation, operative procedure, peri-operative care, prognostic factor, and post-operative adjuvant therapy. | Shintaro Yamazaki Tadatoshi Takayama | 2008 | World Journal of Gastroenterology2008，14，5： | 8 |
| 3 | A Snapshot of the Effective Indications and Results of Surgery for Hepatocellular Carcinoma in Tertiary Referral Centers: Is It Adherent to the EASL/AASLD Recommendations?: An Observational Study of the HCC East-West Study Group显示文摘 | Guido Torzilli Jacques Belghiti Norihiro Kokudo Tadatoshi Takayama Lorenzo Capussotti Gennaro Nuzzo Jean-Nicolas Vauthey Michael A. Choti Eduardo De Santibanes Matteo Donadon Emanuela Morenghi Masatoshi Makuuchi | 2013 | Annals of Surgery2013，，5： | 7 |
| 4 | Prognostic Impact of Anatomic Resection for Hepatocellular Carcinoma显示文摘 | Kiyoshi Hasegawa Norihiro Kokudo Hiroshi Imamura Yutaka Matsuyama Taku Aoki Masami Minagawa Keiji Sano Yasuhiko Sugawara Tadatoshi Takayama Masatoshi Makuuchi | 2005 | Annals of Surgery2005，，2： | 6 |
| 5 | Management before hepatectomy for hepatocellular carcinoma with cirrhosis显示文摘The global distribution of hepatocellular carcinoma(HCC) varies markedly among regions, and patients in East Asia and Central Africa account for about 80% of all cases. The risk factors are hepatitis B, hepatitis C, alcohol, and etc. The risk of carcinogenesis further increases with progression to hepatic cirrhosis in all liver disorders. Radical treatment of HCC by liver resection without causing liver failure has been established as a safe approach through selection of an appropriate range of resection of the damaged liver. This background indicates that both evaluation of hepatic functional reserve and measures against concomitant diseases such as thrombocytopenia accompanying portal hypertension, prevention of rupture of esophageal varices, reliable control of ascites, and improvement of hypoalbuminemia are important issues in liver resection in patients with hepatic cirrhosis. We review the latest information on perioperative management of liver resection in HCC patients with hepatic cirrhosis. | Hisashi Nakayama Tadatoshi Takayama | 2015 | World Journal of Hepatology2015，7，20： | 6 |
| 6 | Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma显示文摘 | Masatoshi Kudo Kazuho Imanaka Nobuyuki Chida Kohei Nakachi Won-Young Tak Tadatoshi Takayama Jung-Hwan Yoon Takeshi Hori Hiromitsu Kumada Norio Hayashi Shuichi Kaneko Hirohito Tsubouchi Dong Jin Suh Junji Furuse Takuji Okusaka Katsuaki Tanaka Osamu Matsui | 2011 | European Journal of Cancer2011，，14： | 5 |
| 7 | Contrast-enhanced ultrasonographic findings of serum amyloid A-positive hepatocellular neoplasm: Does hepatocellular adenoma arise in cirrhotic liver?显示文摘Hepatocellular adenoma(HCA) was recently classified into four pathological subtypes. There have been few studies describing the findings of contrast-enhanced ultrasonography(CEUS) of each type. Our case concerns a 78-year-old man who had undergone routine medical check-ups for hepatitis C for 11 years. Abdominal ultrasonography showed a 28 mm, hypo-echoic mass in the segment 4 of the liver. His integrating amount of drinking was 670 kg convert into ethanol. CEUS with Sonazoid demonstrated mild uniform hypo-enhancement with inflow of microbubbles from the periphery of the tumor in the arterial phase, and heterogeneously hypo-enhancement in the post vascular phase. Because the mass increased in size within 3 mo, a well differentiated hepatocellular carcinoma was suspected, and hepatic resection was performed. Microscopic findings showed homogeneous cell proliferation with low grade atypia, infiltration of inflammatory cells, ductular reactions, fatty deposit in part, and sinusoidal dilation. Immunohistochemistry revealed geographic positive for serum amyloid A(SAA), focal positive for glutaminesynthetase, diffuse and strong positive for C-reactive protein, and positive for liver-type fatty acid binding protein. These pathological features corresponded to that of an inflammatory HCA. However, we could not make a clear diagnosis, because HCAs were defined as not to arise in cirrhotic liver. Finally, this tumor was diagnosed as a SAA positive hepatocellular neoplasm. | Mariko Kumagawa Naoki Matsumoto Yukinobu Watanabe Midori Hirayama Takao Miura Hiroshi Nakagawara Masahiro Ogawa Shunichi Matsuoka Mitsuhiko Moriyama Tadatoshi Takayama Masahiko Sugitani | 2016 | World Journal of Hepatology2016，8，26： | 4 |
| 8 | Klotho in Osx+-mesenchymal progenitors exerts pro-osteogenic and anti-inflammatory effects during mandibular alveolar bone formation and repair显示文摘Maxillofacial bone defects are commonly seen in clinical practice.A clearer understanding of the regulatory network directing maxillofacial bone formation will promote the development of novel therapeutic approaches for bone regeneration.The fibroblast growth factor(FGF)signalling pathway is critical for the development of maxillofacial bone.Klotho,a type I transmembrane protein,is an important components of FGF receptor complexes.Recent studies have reported the presence of Klotho expression in bone.However,the role of Klotho in cranioskeletal development and repair remains unknown.Here,we use a genetic strategy to report that deletion of Klotho in Osx-positive mesenchymal progenitors leads to a significant reduction in osteogenesis under physiological and pathological conditions.Klotho-deficient mensenchymal progenitors also suppress osteoclastogenesis in vitro and in vivo.Under conditions of inflammation and trauma-induced bone loss,we find that Klotho exerts an inhibitory function on inflammation-induced TNFR signaling by attenuating Rankl expression.More importantly,we show for the first time that Klotho is present in human alveolar bone,with a distinct expression pattern under both normal and pathological conditions.In summary,our results identify the mechanism whereby Klotho expressed in Osx+-mensenchymal progenitors controls osteoblast differentiation and osteoclastogenesis during mandibular alveolar bone formation and repair.Klotho-mediated signaling is an important component of alveolar bone remodeling and regeneration.It may also be a target for future therapeutics. | Yi Fan Chen Cui Clifford JRosen Tadatoshi Sato Ruoshi Xu Peiran Li Xi Wei Ruiye Bi Quan Yuan Chenchen Zhou | 2022 | Signal Transduction and Targeted Therapy2022，7，6： | 3 |
| 9 | Long-Term Outcome of Extended Hemihepatectomy for Hilar Bile Duct Cancer With No Mortality and High Survival Rate显示文摘 | Yasuji Seyama Keiichi Kubota Keiji Sano Tamaki Noie Tadatoshi Takayama Tomoo Kosuge Masatoshi Makuuchi | 2003 | Annals of Surgery2003，，1： | 3 |
| 10 | Evidence‐based C linical P ractice G uidelines for H epatocellular C arcinoma: The J apan S ociety of H epatology 2013 update (3rd JSH‐HCC G uidelines)显示文摘 | Norihiro Kokudo Kiyoshi Hasegawa Masaaki Akahane Hiroshi Igaki Namiki Izumi Takafumi Ichida Shinji Uemoto Shuichi Kaneko Seiji Kawasaki Yonson Ku Masatoshi Kudo Shoji Kubo Tadatoshi Takayama Ryosuke Tateishi Takashi Fukuda Osamu Matsui Yutaka Matsuyama Ta | 2015 | Hepatol Res2015，，2： | 2 |
| 11 | Role of surgical resection for hepatocellular carcinoma based on Japanese clinical guidelines for hepatocellular carcinoma显示文摘In the Algorithm for Diagnosis and Treatment in the Japanese Evidence-Based Clinical Practice Guidelines for Hepatocellular Carcinoma, the treatment strategy is determined by three major factors: liver function and the number and size of tumors. The algorithm is quite simple, consisting of fewer components than the Barcelona-Clinic Liver Cancer staging system. In this article, we describe the roles of the treatment algorithmin hepatectomy and perioperative management of hepatocellular carcinoma. | Hisashi Nakayama Tadatoshi Takayama | 2015 | World Journal of Hepatology2015，7，2： | 2 |
| 12 | Frequent β-catenin aberration in human hepatocellular carcinoma显示文摘 | Hajime Fujie Kyoji Moriya Yoshizumi Shintani Takeya Tsutsumi Tadatoshi Takayama Masatoshi Makuuchi Satoshi Kimura Kazuhiko Koike | 2001 | Hepatology Research2001，，1： | 2 |
| 13 | Anatomical keys and pitfalls in living donor liver transplantation显示文摘 | Hiroshi Imamura Masatoshi Makuuchi Yoshihiro Sakamoto Yasuhiko Sugawara Keiji Sano Ataru Nakayama Seiji Kawasaki Tadatoshi Takayama | 2000 | Journal of Hepato - Biliary - Pancreatic Surgery2000，，4： | 2 |
| 14 | Selection Criteria for Hepatectomy in Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombus显示文摘 | Masami Minagawa Masatoshi Makuuchi Tadatoshi Takayama Kuni Ohtomo | 2001 | Annals of Surgery2001，，3： | 2 |
| 15 | Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial显示文摘 | Tadatoshi Takayama Teruaki Sekine Masatoshi Makuuchi Susumu Yamasaki Tomoo Kosuge Junji Yamamoto Kazuaki Shimada Michiie Sakamoto Setsuo Hirohashi Yasuo Ohashi Tadao Kakizoe | 2000 | 2000 (9232)2000，，9232： | 2 |
| 16 | Preoperative Portal Embolization in Patients with Hepatocellular Carcinoma显示文摘 | Yasuhiko Sugawara M.D. Junji Yamamoto M.D. Hisato Higashi M.D. Susumu Yamasaki M.D. Kazuaki Shimada M.D. Tomoo Kosuge M.D. Tadatoshi Takayama M.D. Masatoshi Makuuchi M.D | 2002 | World Journal of Surgery2002，，1： | 1 |
| 17 | Restrictive versus liberal blood transfusion policy for hepatectomies in cirrhotic patients显示文摘 | Masatoshi Makuuchi M.D. Tadatoshi Takayama M.D. Peter Gunvén M.D. Tomoo Kosuge M.D. Susumu Yamazaki M.D. Hiroshi Hasegawa M.D | 1989 | World Journal of Surgery1989，，5： | 1 |
| 18 | Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy显示文摘 | Hiroshi Imamura Yutaka Matsuyama Eiji Tanaka Takao Ohkubo Kiyoshi Hasegawa Shinichi Miyagawa Yasuhiko Sugawara Masami Minagawa Tadatoshi Takayama Seiji Kawasaki Masatoshi Makuuchi | 2002 | Journal of Hepatology2002，，2： | 1 |
| 19 | Reply to correlation between indocyanine green retention test and esophageal varices among patients with hepatocellular carcinoma显示文摘 | Shintaro Yamazaki Tadatoshi Takayama | 2014 | Journal of Gastroenterology2014，，5： | 1 |
| 20 | Preoperative Portal Embolization in Patients with Hepatocellular Carcinoma显示文摘 | Yasuhiko Sugawara M.D. Junji Yamamoto M.D. Hisato Higashi M.D. Susumu Yamasaki M.D. Kazuaki Shimada M.D. Tomoo Kosuge M.D. Tadatoshi Takayama M.D. Masatoshi Makuuchi M.D | 2001 | World Journal of Surgery2001，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员